The rationale behind the Wright Medical – Cartiva acquisition

By

Wright Medical Does A Deal Both Opportunistic And Defensive (SeekingAlpha)

Summary

Wright Medical agrees to pay over 10x 12-month revenue for Cartiva, a fast-growing manufacturer of a cartilage replacement implant used in surgical procedures for the big toe.
Cartiva could add over 1% to Wright Medical's long-term growth rate and at higher margins, with worthwhile cross-selling opportunities in the early years.
The deal dilution is less than ideal, but Wright Medical continues to build a differentiated high-growth platform in extremities and post-deal fair value should be above $30/share....

Get access to full posts newsletters, trends, and market reports for only subscribe for $1/day.
Hit the SUBSCRIBE button at the top of the homepage.